1 – 3 of 3
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2024
- 
                        Mark
        Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    
    - Contribution to journal › Article
 
- 2023
- 
                        Mark
        Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
    
    - Contribution to journal › Article
 
- 2021
- 
                        Mark
        EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma : Recommendations for the Second Phase of the COVID-19 Pandemic
    
    - Contribution to journal › Scientific review